Companies and Markets
Market Research A to Z | Company Profiles A to Z | Register | Contact Us
+44 (0) 203 086 8600 Call us on

Stroke: Competing Treatments and Market Entry Considerations

2490

Select License Type

Electronic License

Electronic License

An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.

Site License

Site License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.

Corporate License

Corporate License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

Hard Copy License

Hard Copy License

As described. Hard copy reports are dispatched in the post/mail. However, the majority of our reports are in PDF and are either available for immediate download or they are sent by email within hours of purchase.

Disk License

Disk License

As described. The CD-Rom (where available) is dispatched in the post/mail. However, the majority of our reports are in PDF and are either available for immediate download or they are sent by email within hours of purchase.

£2,490.00

Change Currency

GBP EURO USD

Market

Healthcare and Medical

Report Type

Market Research

Country

Global

Published

1 June 2010

Number of Pages

140

Report Delivery

Email

Delivery Lead Time

1-3 hours, 24 hour max

Publisher

Biopharm Reports

File Format

-

This report presents the findings of a global clinical survey on competing treatments for Ischaemic Stroke, Haemorrhagic Stroke and Transient Ischaemic Attack (TIA). These findings were made following the participation of more than 230 clinics worldwide, which provided detailed information of their treatment practices. This survey was carried out to evaluate competing therapies and market entry factors, relating to the treatment of Stroke.

In 2008, the World Stroke Congress reported that 20 million Stroke events occur globally each year and account for 5.7 million deaths. Stroke is now the second most common cause of death worldwide and a major cause of disability. The incidence of Stroke is expected to increase by 30% over the next decade (6th World Stroke Congress, Vienna, Austria, 24th-27th September 2008).

In a field where therapies are often unsatisfactory, physicians seek to extend their understanding and use of available treatments to improve patient outcomes. Knowledge in these areas is also important to drug developers, who seek a better understanding of prescribing practices and treatment needs and limitations from the clinician's perspective, as part of their own efforts to develop more effective therapies. To meet interest in these areas, Biopharm Reports has conducted a global survey on current treatments and drug prescribing practices for Stroke. This survey involved the participation of more than 230 clinical centres in 41 countries.

Overview:


Global quantitative data on treatments and drug prescribing practices for Ischaemic Stroke, Haemorrhagic Stroke and Transient Ischaemic Attack (TIA), provided by more than 230 clinics in 41 countries.


More than 98% of study participants are practicing physicians, working in areas of Stroke treatment. Of these, 65% are specialists in Stroke treatment. Leading participant countries were USA, Italy, India, Canada, Japan, Germany, Spain, Belgium and China.


More than 60% of the clinical centres participating in this study were hospital specialist Stroke units, specialist Stroke practices or private Stroke clinics.


Detailed information on drugs classes used in the treatment of patients with Ischaemic Stroke, Haemorrhagic Stroke and Transient Ischaemic Attack (TIA), together with population-based drug prescribing profiles.


Quantitative prescribing data on specific antiplatelet, anticoagulant, thrombolytic and other drugs used in the treatment of Ischaemic Stroke, Haemorrhagic Stroke and Transient Ischaemic Attack (TIA).


The percentage of Ischaemic Stroke patients prescribed the antiplatelets aspirin (e.g. Aspro®), dipyridamole (e.g. Persantine®), clopidogrel (e.g. Plavix®), aspirin/dipyridamol (e.g. Asasantin®), ticlopidine (e.g. Ticlid®) and others (specified).


The percentage of Ischaemic Stroke patients prescribed the coagulants warfarin (e.g. Coumadin®), heparin (e.g. Hepalean®), dicoumarol (e.g. Dicoumarol), antithrombin III (e.g. Thrombate III®), argatroban (e.g. Novastan®), bivalirudin (e.g. Angiomax®), sandoparin (e.g. Certoparin®), enoxaparin (e.g. Lovenox®), ethyl biscoumacetate (e.g. Tromexan®), nadroparin (e.g. Fraxiparine®) or others (specified)


The percentage of Ischaemic Stroke patients prescribed the thrombolytic drug Tissue Plasminogen Activator (e.g. Alteplase®) or others (specified).


The percentage of Haemorrhagic Stroke patients prescribed clotting factor (e.g. vitamin K), clotting proteins (e.g. prothrombin), calcium channel blockers (e.g. nimodipine), antihypertensives, platelets, plasma or other (specified).


Prescribing practices on the use of specific drug combinations, used in the treatment of Ischaemic and Haemorrhagic Stroke.


The percentage of Haemorrhagic Stroke patients treated surgically by aneurysm clipping, endovascular treatment of aneurysms, surgical arteriovenous malformation (AVM) removal, steriotactic radiosurgery, endovascular treatment of AVMs, removal of haematoma, ventriculostomy, carotid endarterectomy, craniotomy and others (specified).


From the clinician's perspective: current limitations in the diagnosis and treatment of Stroke.

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

Electronic License

Electronic License

An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.

Site License

Site License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.

Corporate License

Corporate License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

Hard Copy License

Hard Copy License

As described. Hard copy reports are dispatched in the post/mail. However, the majority of our reports are in PDF and are either available for immediate download or they are sent by email within hours of purchase.

Disk License

Disk License

As described. The CD-Rom (where available) is dispatched in the post/mail. However, the majority of our reports are in PDF and are either available for immediate download or they are sent by email within hours of purchase.

£2,490.00

Change Currency

GBP EURO USD

Visitor Comments

All posts are pre-moderated and must obey the house rules.

Change Currency

GBP
USD

Use our research skills: Get free support

Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support

eBrandPromote: Get your brands ranked highly online

eBrandPromote: Let us promote your brand online through article writing, press release distribution, social media and search engine marketing services. Click here to download our eBrandPromote brochure.

Accessibility
Close

Contrast settings

Text size settings